Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech center experience

被引：5
|
作者：
Weinbergerova, Barbora [1 ,2 ]
Cernan, Martin [3 ,4 ]
Kabut, Tomas [1 ,2 ]
Semerad, Lukas [1 ,2 ]
Podstavkova, Natalia [1 ,2 ]
Szotkowski, Tomas [3 ,4 ]
Jeziskova, Ivana
Mayer, Jiri [1 ,2 ]
机构：
[1] Masaryk Univ, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[2] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[3] Palacky Univ Olomouc, Fac Med & Dent, Dept Hemato Oncol, Olomouc, Czech Republic
[4] Univ Hosp Olomouc, Olomouc, Czech Republic
来源：
HAEMATOLOGICA | 2023年 / 108卷 / 10期
关键词：
CHEMOTHERAPY;
D O I：
10.3324/haematol.2022.282263
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2826 / 2829
页数：4
相关论文
共 50 条
  • [41] Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
    Ravandi, Farhad
    Alattar, Mona Lisa
    Grunwald, Michael R.
    Rudek, Michelle A.
    Rajkhowa, Trivikram
    Richie, Mary Ann
    Pierce, Sherry
    Daver, Naval
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Nazha, Aziz
    Konopleva, Marina
    Borthakur, Gautam
    Burger, Jan
    Kadia, Tapan
    Dellasala, Sara
    Andreeff, Michael
    Cortes, Jorge
    Kantarjian, Hagop
    Levis, Mark
    BLOOD, 2013, 121 (23) : 4655 - 4662
  • [42] Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain
    Solana-Altabella, Antonio
    Boluda, Blanca
    Rodriguez-Veiga, Rebeca
    Cano, Isabel
    Acuna-Cruz, Evelyn
    Blanco, Albert
    Marco-Ayala, Javier
    de la Puerta, Rosalia
    Diaz-Gonzalez, Alvaro
    Pinana, Jose L.
    Sanz, Jaime
    Sempere, Amparo
    Cervera, Jose
    Barragan, Eva
    Sargas, Claudia
    Ballesta-Lopez, Octavio
    Megias-Vericat, Juan Eduardo
    Martinez-Cuadron, David
    Sanz, Miguel A.
    Montesinos, Pau
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (05) : 724 - 733
  • [43] Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
    Vives, Susana
    Quintela, David
    Morgades, Mireia
    Cano-Ferri, Isabel
    Serrano, Alfons
    Acuna-Cruz, Evelyn
    Cervera, Marta
    Diaz-Beya, Marina
    Vidriales, Belen
    Raposo-Puglia, Jose angel
    Arnan, Montserrat
    Garrido, Ana
    Balerdi, Amaia
    Cabello, Ana Isabel
    Herrera-Puente, Pilar
    Serrano, Josefina
    Coll, Rosa
    Tormo, Mar
    Lopez-Marin, Javier
    Garcia-avila, Sara
    Casado, Maria Soledad
    Padilla, Irene
    Rodriguez-Macias, Gabriela
    Calbacho, Maria
    Puchol, Ana
    Hernandez, Agustin
    Torres, Melissa
    Costilla, Lissette
    Colorado, Maria Mercedes
    Martinez-Cuadron, David
    Esteve, Jordi
    Montesinos, Pau
    CETLAM Grp
    PETHEMA Grp
    CANCERS, 2024, 16 (23)
  • [44] Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study
    Orvain, Corentin
    Bertoli, Sarah
    Peterlin, Pierre
    Desbrosses, Yohann
    Dumas, Pierre-Yves
    Iat, Alexandre
    Carre, Martin
    Tavernier, Emmanuelle
    Riou, Jeremie
    Bouvier, Anne
    Bidet, Audrey
    Tondeur, Sylvie
    Renosi, Florian
    Mozziconacci, Marie-Joelle
    Flandrin-Gresta, Pascale
    Dadone-Montaudie, Berengere
    Delabesse, Eric
    Pigneux, Arnaud
    Hunault-Berger, Mathilde
    Recher, Christian
    LEUKEMIA, 2024, 38 (09) : 1949 - 1957
  • [45] Trial in Progress: A Phase 3, Randomized, Double-Blind Study of Midostaurin in Combination with Chemotherapy and as Single-Agent Maintenance Therapy in Newly Diagnosed Patients with FLT3 Mutation-Negative Acute Myeloid Leukemia
    Doehner, Hartmut
    Sierra, Jorge
    Stone, Richard
    Hoenekopp, Albert
    Berkowitz, Noah
    Sachs, Carolin
    Bengoudifa, Bourras-Rezki
    Ossenkoppele, Gert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S206 - S207
  • [46] FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis
    Fei, Xinhong
    Zhang, Shuqin
    Gu, Jiangying
    Wang, Jingbo
    CANCER MEDICINE, 2023, 12 (06): : 6877 - 6888
  • [47] Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
    Yu, Sijian
    Zhang, Yu
    Yu, Guopan
    Wang, Yu
    Shao, Ruoyang
    Du, Xin
    Xu, Na
    Lin, Dongjun
    Zhao, Weihua
    Zhang, Xiong
    Xiao, Jie
    Sun, Zhiqiang
    Deng, Lan
    Liang, Xinquan
    Zhang, Hongyu
    Guo, Ziwen
    Dai, Min
    Shi, Pengcheng
    Huang, Fen
    Fan, Zhiping
    Liu, Qiong
    Lin, Ren
    Jiang, Xuejie
    Xuan, Li
    Liu, Qifa
    Jin, Hua
    JOURNAL OF INTERNAL MEDICINE, 2024, 295 (02) : 216 - 228
  • [48] Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
    Fischer, Thomas
    Stone, Richard M.
    DeAngelo, Daniel J.
    Galinsky, Ilene
    Estey, Elihu
    Lanza, Carlo
    Fox, Edward
    Ehninger, Gerhard
    Feldman, Eric J.
    Schiller, Gary J.
    Klimek, Virginia M.
    Nimer, Stephen D.
    Gilliland, D. Gary
    Dutreix, Catherine
    Huntsman-Labed, Alice
    Virkus, Jodi
    Giles, Francis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4339 - 4345
  • [49] Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation
    Nagler, Arnon
    Labopin, Myriam
    Craddock, Charles
    Socie, Gerard
    Yakoub-Agha, Ibrahim
    Gedde-Dahl, Tobias
    Niittyvuopio, Riitta
    Byrne, Jennifer Louise
    Cornelissen, Jan J.
    Labussiere-Wallet, Helene
    Arcese, William
    Milpied, Noel
    Esteve, Jordi
    Canaani, Jonathan
    Mohty, Mohamad
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 274 - 282
  • [50] Patients with TP53-Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study
    Sumransub, Nuttavut
    Steinwand, Gabriel K.
    Cordner, Keith
    Lee, Yoonkyu
    Cao, Qing
    Allred, Jeremy
    Bachanova, Veronika
    Juckett, Mark
    Eckfeldt, Craig
    Maakaron, Joseph E.
    Tracy, Sean I.
    Ramesh, Vidhyalakshmi
    Nelson, Andrew C.
    Yohe, Sophia
    Sachs, Zohar
    CANCERS, 2024, 16 (16)
12345